Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.32 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.32 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.32 |
| ▸ | ITGAL | P20701 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2746875 | 0.81 | CYP2A6 (0.34) | — | |
| SCHEMBL14046758 | 0.77 | PKM (0.33) | — | |
| SCHEMBL11408529 | 0.73 | ALDH1A1 (0.38) | — | |
| SCHEMBL22331573 | 0.69 | — | — | |
| SCHEMBL45637 | 0.69 | ABCG2 (0.36) | ABCG2ITGB2ICAM1ITGAL | |
| SCHEMBL29450629 | 0.67 | ABCG2 (0.40) | ABCG2ITGB2ICAM1ITGAL | |
| SCHEMBL29435911 | 0.67 | ABCG2 (0.40) | ABCG2ITGB2ICAM1ITGAL | |
| SCHEMBL3889220 | 0.67 | ABCG2 (0.40) | ABCG2ITGB2ICAM1ITGAL | |
| SCHEMBL5952003 | 0.67 | — | — | |
| SCHEMBL6419935 | 0.66 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11655261-B2 | Method for preparing 18F-BPA and intermediate | NEUBORON MEDTECH LTD. (CN) | 2023-05-23 | — | — | US | disclosed |
| US-11655261-B2 | Method for preparing 18F-BPA and intermediate | NEUBORON MEDTECH LTD. (CN) | 2023-05-23 | — | — | US | disclosed |
| US-20210230192-A1 | METHOD FOR PREPARING 18F-BPA AND INTERMEDIATE | NEUBORON MEDTECH LTD. (CN) | 2021-07-29 | — | — | US | disclosed |
| US-10738064-B2 | Chiral α-amino tertiary boronic esters | PURDUE RESEARCH FOUNDATION (US) | 2020-08-11 | — | — | US | disclosed |
| US-9856194-B2 | Catalysts for the production of methanol from carbon dioxide | UNIVERSITé LAVAL (CA) | 2018-01-02 | — | — | US | disclosed |
| US-20170283432-A1 | DERIVATIVES OF MACROCYCLIC N-ARYL-TRICYCLOPYRIMIDINE-2-AMINE POLYETHERS AS INHIBITORS OF FTL3 AND JAK | PIERRE FABRE MEDICAMENT (FR) | 2017-10-05 | — | — | US | disclosed |
| US-20170283432-A1 | DERIVATIVES OF MACROCYCLIC N-ARYL-TRICYCLOPYRIMIDINE-2-AMINE POLYETHERS AS INHIBITORS OF FTL3 AND JAK | PIERRE FABRE MEDICAMENT (FR) | 2017-10-05 | — | — | US | disclosed |
| US-20170281622-A1 | DERIVATIVES OF MACROCYCLIC N-ARYL-2-AMINO-4-ARYL-PYRIMIDINE POLYETHERS AS INHIBITORS OF FTL3 AND JAK | PIERRE FABRE MEDICAMENT (FR) | 2017-10-05 | — | — | US | disclosed |
| US-20170281622-A1 | DERIVATIVES OF MACROCYCLIC N-ARYL-2-AMINO-4-ARYL-PYRIMIDINE POLYETHERS AS INHIBITORS OF FTL3 AND JAK | PIERRE FABRE MEDICAMENT (FR) | 2017-10-05 | — | — | US | disclosed |
| US-20170121295-A1 | POLYCYCLIC LPA1 ANTAGONIST AND USES THEREOF | AMIRA PHARMACEUTICALS, INC. (US) | 2017-05-04 | — | — | US | disclosed |
| US-20120053170-A1 | NICOTINAMIDE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF AS ANTICANCER DRUGS | SANOFI (FR) | 2012-03-01 | — | — | US | disclosed |
| US-20120004404-A1 | RADIOLABELLING METHODS | HAMMERSMITH IMANET LIMITED (GB) | 2012-01-05 | — | — | US | disclosed |
| US-20110251194-A1 | ANTINEOPLASTIC DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2011-10-13 | — | — | US | disclosed |
| US-20110160249-A1 | 5-LIPOXYGENASE-ACTIVATING PROTEIN INHIBITOR | AMIRA PHARMACEUTICALS, INC. | 2011-06-30 | — | — | US | disclosed |
| US-20100222319-A1 | NICOTINAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-09-02 | — | — | US | disclosed |
| US-7704752-B2 | Signalling compounds for use in methods of detecting hydrogen peroxide | LUMIGEN, INC. (US) | 2010-04-27 | — | — | US | disclosed |
| US-20100055800-A1 | Compositions for Chemiluminescent Detection of Hydrogen Peroxide | LUMIGEN, INC. (US) | 2010-03-04 | — | — | US | disclosed |
| US-20090291981-A1 | 5-Lipoxygenase-Activating Protein Inhibitor | AMIRA PHARMACEUTICALS, INC. (US) | 2009-11-26 | — | — | US | disclosed |
| US-20080261318-A1 | Signalling Compounds For Use In Methods Of Detecting Hydrogen Peroxide | LUMIGEN, INC. (US) | 2008-10-23 | — | — | US | disclosed |
| US-7390670-B2 | Signalling compounds and methods for detecting hydrogen peroxide | LUMIGEN, INC. (US) | 2008-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170121295-A1 | POLYCYCLIC LPA1 ANTAGONIST AND USES THEREOF | LPAR1, LPAR2, LPAR4 | ABCG2 2042/4885ITGB2 3542/4885ICAM1 2489/4885 |
| US-20170283432-A1 | DERIVATIVES OF MACROCYCLIC N-ARYL-TRICYCLOPYRIMIDINE-2-AMINE POLYETHERS AS INHIBITORS OF FTL3 AND JAK | JAK2, JAK3, JAK1 | ABCG2 3839/4885ITGB2 2946/4885ICAM1 4814/4885 |
| US-20110160249-A1 | 5-LIPOXYGENASE-ACTIVATING PROTEIN INHIBITOR | ALOX5, PRMT5, ALOX5AP | ABCG2 4255/4885ITGB2 4340/4885ICAM1 3643/4885 |
| US-20120053170-A1 | NICOTINAMIDE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF AS ANTICANCER DRUGS | NAMPT, NNT, NQO1 | ABCG2 223/4885ITGB2 2963/4885ICAM1 4169/4885 |
| US-20120004404-A1 | RADIOLABELLING METHODS | ARFGEF1, TMEM14C, PIGO | ABCG2 608/4885ITGB2 2356/4885ICAM1 3508/4885 |
| US-20090291981-A1 | 5-Lipoxygenase-Activating Protein Inhibitor | ALOX5, LTA4H, ALOX5AP | ABCG2 3027/4885ITGB2 4646/4885ICAM1 4264/4885 |
| US-20210230192-A1 | METHOD FOR PREPARING 18F-BPA AND INTERMEDIATE | CYP19A1, SHBG, ESR1 | ABCG2 460/4885ITGB2 3140/4885ICAM1 4361/4885 |
| US-20110251194-A1 | ANTINEOPLASTIC DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | MCL1, PAICS, SLCO1B1 | ABCG2 8/4885ITGB2 3496/4885ICAM1 4854/4885 |
| US-11655261-B2 | Method for preparing 18F-BPA and intermediate | CYP19A1, SHBG, ESR1 | ABCG2 460/4885ITGB2 3140/4885ICAM1 4361/4885 |
| US-20170281622-A1 | DERIVATIVES OF MACROCYCLIC N-ARYL-2-AMINO-4-ARYL-PYRIMIDINE POLYETHERS AS INHIBITORS OF FTL3 AND JAK | JAK2, JAK3, JAK1 | ABCG2 3406/4885ITGB2 3014/4885ICAM1 4809/4885 |
| US-20100222319-A1 | NICOTINAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | NNT, NAMPT, NQO1 | ABCG2 414/4885ITGB2 1099/4885ICAM1 4167/4885 |
| US-10738064-B2 | Chiral α-amino tertiary boronic esters | HBB, BCAT1, BCAT2 | ABCG2 1951/4885ITGB2 1735/4885ICAM1 4516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.